# Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

> **NCT04540120** · PHASE2 · TERMINATED · sponsor: **Olatec Therapeutics LLC** · enrollment: 49 (actual)

## Conditions studied

- Covid19
- Cytokine Release Syndrome

## Interventions

- **DRUG:** dapansutrile capsules
- **DRUG:** placebo capsules

## Key facts

- **NCT ID:** NCT04540120
- **Lead sponsor:** Olatec Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-24
- **Primary completion:** 2022-07-28
- **Final completion:** 2022-07-28
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Terminated due to the treatment environment for COVID-19 evolving with the pervasiveness of vaccinations and other therapeutic modalities in mitigating against severe infection that has eliminated a viable patient population for study enrollment.
- **Last updated:** 2023-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540120, "Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04540120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*